Updated guidance. The guidance provides useful information to staff working in prisons, as well as to health and prison authorities, explaining how to prevent and address a potential outbreak of COVID-19. In addition, it aims to protect the health and well-being of all those who live and work in, an...d visit, these settings and the general population at large. People deprived of their liberty, and living or working in enclosed environments in close proximity, are likely to be more vulnerable to the COVID-19 disease than the general population. Moreover, correctional facilities may amplify and enhance COVID-19 transmission beyond their walls.
more
2020 was a year like no other. Amidst on-going humanitarian crises, largely fuelled by conflict and violence but also driven by the effects of climate change – such as the largest locust infestation in a generation – the world had to contend with a global pandemic. In less than one year (March-D...ecember 2020), more than 82 million COVID-19 cases and 1.8 million deaths were recorded. In that timeframe, out of the global COVID-19 totals, 30 per cent of COVID-19 cases and 39 per cent deaths were recorded in GHRP countries.
more
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
This report provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States. It presents the number of vaccine doses distributed by manufacturers to each Member State for the different approved vaccines and the number of first..., second or unspecified doses administered to adult individuals overall, by age group and other selected target groups including healthcare workers (HCW) and residents in long-term care facilities (LTCF).
more
04.März 2021
MEDBOX Issue Brief no. 10
Dieser Issue Brief gibt einen kurzen Überblick über Teststrategie, Testverfahren, Videos zur Handhabung und weiterführende Literatur.
Contact tracing is a key element of WHO’s recommended approach to control the spread of COVID-19 by breaking the chains of human-to-human transmission.
This document provides guidance to health authorities at all levels to improve the success rate of contact tracing by informing efforts with RCCE... principles, evidence and activities, and provides ready-to-use tools for professionals involved in contact-tracing efforts to inform their practices with RCCE principles and likewise improve their success rate.
more
This document is an update of the guidance published on 21 March 2020 and contains new evidence and guidance.
Наряду с тщательным тестированием, изоляцией и уходом за заболевшими отслеживание контактов является ведущей стратегией для прерывания цепочек передачи вируса SA...RS-CoV -2 и снижения смертности, связанной с COVID-19.
more
Основные аспекты обеспечения биологической безопасности в лабораторных условиях в связи с распространением вируса SARS-CoV
28 January 2021. The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients.
Integrated Monitoring Flowchart for patients suspected of Dengue and/or COVID-19
Additional dose of the primary vaccination against COVID-19: Technical Guidelines
Guidelines for diagnosis, acute care and post-COVID-19 follow-up for children and adolescents
Emergency medical teams (EMTs) play an important role in strengthening health service networks in terms of their strategies and tactics for planning mass vaccination programs, especially in remote or under-resourced areas or those overwhelmed by COVID-19. EMTs experience deploying in remote areas an...d handling operational challenges to ensure their response even under the most austere conditions will be of great support in facing the technical and logistical challenges to timely and equitable access to vaccines at the local level.
more
The COVID-19 pandemic has impacted regular cardiovascular healthcare access and delivery. Service utilisation has declined, and excess cardiovascular mortality has been reported in several countries. We aim to estimate excess cardiovascular deaths in Chile during 2020.